Secondary Logo

COX-2 Inhibitors and Cardiovascular Risk

Funk, Colin D PhD*; FitzGerald, Garret A MD

Journal of Cardiovascular Pharmacology: November 2007 - Volume 50 - Issue 5 - p 470-479
doi: 10.1097/FJC.0b013e318157f72d
Invited Review
Free

Placebo-controlled trials of nonsteroidal antiinflammatory drugs (NSAIDs) selective for COX-2 have revealed an enhanced risk for cardiovascular events. COX-2 inhibitors (coxibs) selectively reduce vascular prostacyclin synthesis without disrupting COX-1-derived thromboxane synthesis in platelets. Removal of prostacyclin's capacity to restrain all known endogenous compounds contributing to platelet activation and vasoconstriction is a well-recognized mechanism for coxib action in the cardiovascular system which can pre-dispose to thrombosis, hypertension and atherosclerosis. Novel mouse models of selective COX-2 inhibition and disruption of microsomal prostaglandin E synthase-1 have been exploited to reveal the relative importance of prostacyclin and prostaglandin E2 in cardiovascular homeostasis. This review discusses the background to our current understanding of coxibs and provides further information relating to recent mechanistic insights into how COX-2 inhibition promotes cardiovascular risk.

From the *Departments of Biochemistry and Physiology, Queen's University, Kingston, Ontario, Canada; and †Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania.

Received for publication May 11, 2007; accepted August 7, 2007.

This work was supported by Canadian Institutes of Health Research (MOP-79459), Heart and Stroke Foundation of Canada (NA5828) grants (to CDF) and by National Institutes of Health (HL083799, HL62250, and RR023567) grants (to GAF). CDF is a Tier I Canada Research Chair in Molecular, Cellular and Physiological Medicine and holder of a Career Investigator Award from the Heart and Stroke Foundation of Ontario. GAF is McNeill Professor of Translational Medicine and Therapeutics.

GAF receives financial support for investigator-initiated research from Bayer, Merck, and Boehringer Ingelheim, all of which manufacture drugs that target COXs. This author has also served as a consultant for Astra Zeneca, Bayer, Biolipox, Boehringer Ingelheim, deCode, Merck, GlaxoSmithKline, Genome Institute of the Novartis Foundation, Lilly, Novartis, NicOx and VIA Pharmaceuticals.

CDF has received financial support for investigator-initiated eicosanoid research from Merck. The author has served as a consultant for Pfizer, Merck, Astra-Zeneca, Bristol Myers Squibb, Critical Therapeutics and for representatives of the multi-district litigation relating to coxibs. CDF is on the scientific advisory board of VIA Pharmaceuticals.

Reprints: Colin D. Funk, PhD, Department of Physiology, Botterell Hall Rm.433 Queen's University, Kingston, ON K7L 3N6 Canada (e-mail: funkc@queensu.ca).

Back to Top | Article Outline

BACKGROUND

Prostaglandins (PGs) are a family of bioactive lipid mediators that are formed from arachidonic acid contained in membranes in virtually all cells of the body.1-4 They are involved in numerous physiological and pathophysiological activities in humans and animals. Prostaglandin H synthase (PGHS), with 2 distinct catalytic activities referred to as cyclooxygenase (COX) and hydroperoxidase, respectively,1-4 carries out the initial transformation of fatty acid. COX is a common way of referring to this prostaglandin-synthesizing enzyme. About 10 years after the initial isolation of PGD2, PGE2, and PGF (the classical prostaglandins), between 1962 and 1964 an unstable compound, TxA2 was identified by Samuelsson and co workers.5-8 Moncada, Bunting, and Vane were the first to describe the formation of a prostaglandin substance, first called PGX, in 1976 as an unstable substance that inhibits platelet aggregation.9,10 Its chemical structure was quickly elucidated and was termed prostacyclin by the end of the same year.11 During the early 1970s, the research of Vane, Flower, and Moncada's group led to the understanding that nonsteroidal antiinflammatory drugs (NSAIDs) can block the synthesis of prostaglandins that represented a monumental advance, explaining the mechanism of action of these most commonly consumed of all drugs.12-14 There are additional enzymes required to transform the PGH2 intermediate derived from COX (PGD, PGE, PGF, PGI, and Tx synthases) into the 5 prostaglandins. Until 1989, researchers were under the distinct impression that there was only 1 COX enzyme or isoform, and this was reinforced by the cloning of only 1 DNA sequence for a COX gene from sheep15,16 and 1 from humans17 during 1988 and 1989.

Back to Top | Article Outline

THE DISCOVERY OF A SECOND CYCLOOXYGENASE

During the late eighties, 3 separate research groups independently described experiments suggesting that a second form of COX, one that is inducible, might exist.18-21 Using sheep trachea epithelial cultured cells, Holtzman's group18 identified increased COX activity that did not correlate with the only known COX gene known at the time (a 2.8 kb mRNA). Needleman's team19 found that using human dermal fibroblast interleukin-1, an inflammatory cytokine, could potently induce COX activity and that this induction could be regulated by glucocorticoids. They also found that a COX activity in human monocytes could be controlled by the bacterial substance lipopolysaccharide (LPS), and they postulated that “cells may contain two pools of COX, each with a differential sensitivity to LPS or dexamethasone.”20 Han et al21 detected persistent induction of a COX in viral-transformed mouse 3T3 fibroblasts. However, it took a couple of years before other investigators could connect these early results to a second COX enzyme. Thus, 2 research groups working in completely different experimental systems cloned the gene for a second COX isoform.22,23 Simmon's group22 was working with chicken embryo fibroblasts that were infected with a Rous sarcoma virus and identified a COX-encoding gene with about 60% sequence identity to the original COX isoform. Herschmann's group,23-25 on the other hand, identified a COX gene, originally called TIS-10, that was induced by the tumor- promoting substance 12-O-tetradecanoyl phorbol 13-acetate (TPA) in mouse fibroblasts. Around 1992, investigators started referring to the 2 prostaglandin synthase enzymes as PGHS-1 and PGHS-2 or COX-1 and COX-2 when both the human platelet PGHS-1 (COX-1) and human endothelial cell PGHS-2 (COX-2) sequences were cloned and expressed.26-28 In most experimental systems the COX-1 gene does not undergo large changes in gene expression, and this enzyme isoform is often referred to as the housekeeping or constitutive COX, whereas the more recently discovered COX-2 isoform was found to undergo profound regulation by many factors, including cytokines, tumor promoters, inflammatory stimuli, glucocorticoids, etc. As a result, COX-2 is often called the “inducible” or “regulatable” COX isoform.1-4 However, it is now well appreciated that COX-1 may be regulated in its expression while COX-2 expression is constitutive in several organs, including kidney and brain.

Back to Top | Article Outline

THE DEVELOPMENT OF SELECTIVE COX-2 INHIBITORS (COXIBS)

Studies in the early 1990s indicated that the inducible COX-2 was largely responsible for prostaglandin formation associated with inflammation, while COX-1 was important for prostaglandins of housekeeping function (eg, gastric cytoprotection).29-31 Thus, the pharmaceutical industry devoted immediate attention to develop selective COX-2 inhibitors (known as coxibs) on the basis of this COX-2 hypothesis. To do this, experimental assays had to be established to discern the relative potencies of inhibition by drugs of COX-1 and COX-2.32-36 Two leading drug candidates for human development were selected by Pfizer (formerly Monsanto Searle, Pharmacia) and Merck and became known as celecoxib and rofecoxib, respectively.37-40

Celecoxib is a sulfonamide-containing 1,5-diarylpyrazole compound that was identified through in vitro screening and in vivo testing from a structural lead compound SC-236 and was referred to as SC-58635 during development.37 Using in vitro assays, celecoxib was found to have 155-fold to 3200-fold selectivity for COX-2 compared to COX-1.41 The sulfonamide group in celecoxib binds within a side-pocket of the COX-2 active site that is not present in COX-1 and confers the selectivity of the drug. The drug binds in a competitive manner at first and then becomes irreversible.41 Selectivity is greatly influenced by the type of assay and preincubation time period with the inhibitor. Using a whole blood assay (WBA), the selectivity ratio for celecoxib is between 8 and 30.36,42-44

Rofecoxib, 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone, also known as Vioxx, was developed as a highly selective and potent COX-2 inhibitor that showed over 800-fold selectivity in a cell assay system39,43,44 and 35-fold to 272-fold selectivity using the WBA.36,42-44 Various animal studies showed efficacy of rofecoxib in models of inflammation and pain and without GI toxicity.3 Rofecoxib provided dental pain relief on par with NSAIDs (eg, ibuprofen) and significantly greater than placebo.40 Various clinical trials showed efficacy in managing pain in osteoarthritis (OA) and rheumatoid arthritis (RA) without upper gastrointestinal (UGI) complications. The United States Food and Drug Administration approved the therapeutic use of rofecoxib in 1999 at the recommended dose of 25 to 50 mg. The VIoxx Gastrointestinal Outcomes Research study (VIGOR) evaluated about 8000 RA patients in a randomized trial comparing rofecoxib (50 mg/d) to naproxen (500 mg bid) over 9 months.45 This drug was in use for about 5 years when it was removed from the market for reasons mentioned below.

Several coxibs were developed with improved COX-2 selectivity after celecoxib and rofecoxib.3,46-49 These include valdecoxib (Bextra), etoricoxib (Arcoxia), parecoxib and lumiracoxib (Prexige). Parecoxib is a prodrug of valdecoxib that is administered by intravenous or intramuscular injection routes. This drug is converted to the active compound valdecoxib by deoxymethylation.46 Valdecoxib showed efficacy for management of OA, RA, and menstrual pain3 and was approved for use in the United States in 2003, but it has since been withdrawn from the market. The most selective coxib is lumiracoxib and is followed by etoricoxib. The FDA recently failed to approve etoricoxib for sale in the United State, and lumiracoxib is yet to be approved for the US market.

Back to Top | Article Outline

PROSTACYCLIN, THROMBOXANE, AND CARDIOVASCULAR HOMEOSTASIS

Prostacyclin

Prostacyclin (PGI2) is a potent inhibitor of platelet aggregation9,10,50 synthesized by human arterial and venous tissues/cells from arachidonic acid, with highest capacity to synthesize prostacyclin in the arterial endothelium.50-52 Prostacyclin can also be made in other tissues of the body both in the blood vessels within these tissues and the tissues themselves as detected by the mRNA for the main prostacyclin-synthesizing enzyme, prostacyclin synthase.50,53 Prostacyclin can both inhibit platelet clumping and disrupt clumps of previously aggregated platelets.54 It can also promote blood vessel wall relaxation (vasodilatation) and modulate vascular tone50,55 and inhibit proliferation of vascular smooth muscle cells.56 Clinically, PGI2 (epoprostanol) and its analogs are used in the treatment of primary pulmonary hypertension and in treatment of portopulmonary hypertension that arises secondary to liver disease.46,55 In the cardiovascular system, this prostaglandin is generally regarded as an important, beneficial homeostatic regulator to limit thrombosis.

Back to Top | Article Outline

Thromboxane

Thromboxane, an unstable substance derived from arachidonic acid with a half-life of about 30 seconds, is a potent platelet-aggregating agent synthesized within the platelet.8 This powerful platelet-clumping agent synthesized via COX-1 and thromboxane synthase in platelets amplifies the response to other platelet agonists (eg, collagen and ADP).57,58 Besides its effects on platelets, this compound can also constrict blood vessels59 and promote the proliferation of blood vessel smooth muscle cells.60 Activation of this pathway is important in the context of hemostasis.57,61 The importance of this pathway to thrombosis is attested by the findings that a low-dose aspirin regimen has been used by millions as a means to maintain cardiovascular health via its ability to block platelet COX-1-derived thromboxane production. Many clinical trials have shown the benefit of low-dose aspirin in the primary prevention of acute myocardial infarction and in the secondary prevention of myocardial infarction, ischemic stroke, and vascular death.62-68 Dysregulated thromboxane synthesis in the cardiovascular system is regarded as a detrimental event that can lead to thrombosis.

Back to Top | Article Outline

Thromboxane/Prostacyclin “Balance”

Due to the contrasting biological functions of thromboxane and prostacyclin, the concept of balance in the body was first proposed more than 30 years ago10,69,70 for maintenance of healthy cardiovascular status. Vane and colleagues10 stated, “a balance between the amounts of TXA2 formed by platelets and PGX (prostacyclin) formed by vessels might be critical for thrombus formation.” Data from measurements of prostacyclin and thromboxane metabolites (the main urinary metabolites are referred to as PGI-M and Tx-M, respectively) several years later indicated that prostacyclin and thromboxane are formed in small amounts and that they do not act as circulating hormones, but they exert their actions locally in a so-called paracrine/autocrine manner (ie, in the immediate adjacent cells or same cell of synthesis) during platelet-vascular wall interactions.70-75 Thromboxane production by platelets with its pro-platelet activating properties and vascular prostacyclin with its platelet inhibition properties were the key components to this balance. The importance of these 2 eicosanoids has been a reflection of the role thromboxane plays as an amplifying signal for platelet activation by all recognized agonists and the role of prostacyclin as a restraint on all endogenous compounds that promote platelet activation and vasoconstriction.57,76 Indeed, prostacyclin limits platelet activation by thromboxane in vivo and reduces the thrombotic response to vascular injury in mouse models.77 However, this concept of a balance can represent a simplification of the biological context within the vasculature.76,78 These eicosanoids are 1 component of the many facets of an intricately organized and exquisitely regulated vasculature to maintain cardiovascular health. Other cardioprotective mechanisms of the vascular endothelium, in addition to prostacyclin, include nitric oxide (which has similar anti-platelet aggregation and vascular relaxation properties to prostacyclin), CD39 ecto-ADPase [a molecule on the surface of blood vessels that destroys the platelet proaggregating substance adenosine diphosphate (ADP)], thrombomodulin, heparin-like proteoglycan substances, tissue factor pathway inhibitor, and tissue plasminogen activator.76,79,80 Other prothrombotic agents besides thromboxane are thrombin and ADP as well as substances from a perturbed endothelium, which include tissue factor, plasminogen activator inhibitor, von Willebrand factor, collagen, and P-selectin.76,80

Given the important and opposing biological actions of thromboxane and prostacyclin, there have been attempts to define therapies that might depress or block thromboxane while leaving prostacyclin synthesis intact. Such biochemical selectivity could only partially be attained with conventionally formulated low-dose aspirin,81,82 although exploitation of aspirin action on platelets in the presystemic circulation permitted development of a selective formulation.83

Back to Top | Article Outline

MAJORITY OF PROSTACYCLIN SYNTHESIS DERIVES FROM COX-2 AND NOT COX-1

COX-1 was generally regarded as the main enzyme capable of forming both thromboxane and prostacyclin in blood platelets and the vascular wall before studies of human pharmacology that ascribed prostacyclin biosynthesis predominantly to COX-2 instead of COX-1.84 In this study and others, urinary PGI-M metabolite, an index of systemic biosynthesis of prostacyclin, derived mainly (about 65% to 80%) from COX-2 and thromboxane synthesis from COX-1.84-86 These conclusions were drawn initially on the basis of administration of celecoxib (a selective COX-2 inhibitor) and ibuprofen (a mixed COX-1/COX-2 inhibitor). Another parallel study revealed that rofecoxib (Vioxx; MK-966) caused a similar suppression of PGI-M.85 An additional study using nimesulide, a partially selective COX-2 inhibitor, showed that both COX-1 and COX-2 can contribute to prostacyclin production in patients with atherosclerosis.87 These studies, therefore, indicated that COX-2 inhibitors could be harmful in the cardiovascular system by blocking prostacyclin biosynthesis without affecting thromboxane production, in effect yielding a more favorable prothrombotic state.

Back to Top | Article Outline

MECHANISMS BY WHICH COX-2 INHIBITION PROMOTES CARDIOVASCULAR INJURY

Loss of Vascular Prostacyclin Synthesis Without Alteration in Platelet Thromboxane Synthesis Enhances Thrombotic Risk, Hypertension, and Atherosclerosis

The most straightforward explanation for the mechanistic basis by which COX-2 inhibition advances cardiovascular hazard is through experiments and clinical studies that show a decrease in COX-2 vascular prostacyclin production without a concomitant change in thromboxane levels. This leads to a state that is predisposed to thrombosis, hypertension, and atherosclerosis. Celecoxib or rofecoxib administration to volunteers causes a 65% to 80% decrease in prostacyclin synthesis from COX-2 on the basis of urinary metabolite measures as mentioned above.84-86 When blood is removed from these volunteers at peak drug concentration, the ability of the platelets to aggregate ex vivo is not affected as it is with a traditional NSAID (ibuprofen and indomethacin) that blocks both COX-1 and COX-2; consistent with this observation was the finding of no effect on platelet thromboxane synthesis from coxibs. These human studies, therefore, indicate that a constraint on the cardiovascular actions of thromboxane would be removed during coxib therapy.47,48,76,84-86

Key to this proposed mechanism is that COX-2-synthesized prostacyclin is indeed derived from important arterial sources. What is the evidence? Supporting data for the importance of COX-2 in vascular tissue comes from several sources. First, the human gene, or more specifically complementary DNA (cDNA) for COX-2, was first cloned from a blood vessel source, namely endothelial cells derived from human umbilical veins (HUVEC).27,28 Second, the COX-2 gene is induced by laminar shear stress using HUVEC, an in vitro model system, for blood vessels.88-90 This stress on the vascular wall is evident throughout most regions of the vascular tree and can be modeled in cultured cell systems.91 Third, COX-2 mRNA and protein can be found in human and mouse blood vessels in the endothelium and smooth muscle cells to varying degrees in normal and atherosclerotic states using techniques of in situ hybridization and immunohistochemistry.76,87,92-97 Fourth, a florid example of the relevance of COX-2 to vascular function is that in mice deficient in the enzyme, the ductus arteriosus (DA), a vessel that shunts blood away from the high -resistance lungs to the aorta during fetal life, remains patent after birth, resulting in neonatal death in ~40% of newborn mice.98 COX-2 generates PGH2 that is converted not only to prostacyclin but also to PGE2, which activates the EP4 prostaglandin receptor. This activation promotes DA closure via hyaluronic acid-mediated intimal cushion formation, a process that involves enhanced smooth muscle migration and proliferation leading to vascular lumen occlusion.99

The vascular endothelium, especially in areas of disturbed laminar shear where susceptibility to atherogenesis is highest, is under a consistent state of chronic low-grade inflammation.100 This may lead to variable responses to enhance COX-2 expression both in the endothelium and within lesional macrophages. In humans, it has not been possible to document the precise in vivo quantitation of COX-1 versus COX-2 in vascular endothelium throughout the arterial network. Immunohistochemistry techniques indicate COX-1 is found predominantly in normal, healthy blood vessels ex vivo.87,92-95 However, since COX-2 is an immediate-early gene that is induced rapidly and the turnover of COX-2 mRNA and protein is rapid and regulated by posttranscriptional mechanisms,23,101,102 it is likely that ex vivo immunohistochemistry measurements from autopsy specimens have not predicted an accurate amount of COX-2 in the vasculature and perhaps also in animal studies, where tissues can be harvested more quickly. Moreover, it is important to highlight that detection of COX isoforms by immunohistochemistry does not predict the amount of vascular prostacyclin being synthesized by each isoform, especially since COX-2 is much more active than COX-1 at low substrate and hydroperoxide concentrations.103 Even if COX-1 were in relative abundance as assessed by immunohistochemistry, along with the caveat of COX-2 stability vis-a vis COX-1,104 a preponderance of prostacyclin synthesis can result from an apparently low level of COX-2 in the vasculature, which has been mimicked in laminar shear stress-treated endothelial cells in vitro.90 Furthermore, in a novel mouse model in which the COX-1 gene was placed under the control of COX-2 gene regulatory elements, significantly less prostacyclin could be generated than by COX-2 as assessed by urinary PGI-M measures, likely due to the differential hydroperoxide and substrate requirements of the 2 COX isoforms.105

COX-2 inhibitors could be harmful in the cardiovascular system by blocking prostacyclin biosynthesis without affecting thromboxane production, in effect yielding a more favorable prothrombotic state.

Vascular tissue is highly dynamic, acting much more than as a passive conduit of blood.80 The endothelial cells lining the vascular wall are dynamic sensors of wall shear stress and exhibit highly sensitive means of regulation in discrete, localized regions of the vasculature.106,107 This vascular heterogeneity at the level of individual endothelial cells has been examined by microarray analysis.107 COX-2 gene expression has been shown to be modulated by disturbed flow in this setting indicating that there are specific microdomains of the vasculature that express COX-2. In these regions, COX-2 is most likely acting as a cardioprotective mechanism that contributes to prostacyclin biosynthesis.

Assessing the cardiovascular risk with COX-2 inhibition is most easily studied in animal models. A genetic model of selective COX-2 inhibition has been established to investigate this matter by introducing a mutation into the COX-2 gene to disrupt COX activity.108,109 These mice and mice treated with 2 selective COX-2 inhibitors [celecoxib or 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl)phenyl-2(5H)-furanone (DFU)] show decreased urinary measures of PGI-M, just like in humans, with little if any effect on Tx-M urinary metabolites.108 These findings establish mice as a useful model for exploring the effects of COX-2 inhibition on mechanisms for increased cardiovascular risk in humans. In 3 different models of thrombosis, either genetic COX-2 deletion or pharmacological treatment (celecoxib or DFU) led to increased thrombosis.108 Moreover, there were also small but significant increases in both systolic and diastolic blood pressures associated with COX-2 inhibition in the same groups of mice.108

In another series of experiments in dogs, COX-2-derived prostacyclin was implicated in the protective response to induced thrombosis by electrolytic injury in the circumflex coronary artery.110 In these studies, oral aspirin administration combined with an endothelial recovery period after injury markedly prolonged the time to vascular occlusion. This prolongation was abrogated with celecoxib. In addition, the vasodilatory response to arachidonic acid was reduced significantly in celecoxib-treated animals.110

Salt-sensitive rats were shown to have an elevation of blood pressure with COX-2 inhibition using NS-398 and a COX-2 inhibitor (SC-58236, a lead compound in the development of celecoxib).111 Moreover, genetic COX-2 deficiency in mice reduced renal medullary blood flow, decreased urine flow, and enhanced the pressor effect of angiotensin II.112 Intravascular thrombosis was associated with COX-2 inhibition (SC-58236), including suppression of prostacyclin in a model of pulmonary hypertension in rats.113 Similarly, selective COX-2 inhibition with NS-398 suppressed prostacyclin (measured as 6-keto-PGF) and enhanced platelet-vessel wall interactions in vivo and platelet adhesion to hamster cheek pouch arterioles.114 Absence of the prostacyclin receptor, known as IP, which transduces the effects of prostacyclin, augmented the response to a thrombogenic stimulus in mice.115

In human coronary artery smooth muscle cells, prostacyclin stimulates thrombomodulin expression that constrains activation of the blood coagulant thrombin.116 Therefore, blockade of prostacyclin with COX-2 inhibition will lead to enhanced platelet activation and resultant thrombosis by promoting assembly of the prothrombinase complex.

Atherosclerosis is a chronic arterial wall inflammatory disease that develops over decades in humans, but the early stages of fatty streak formation can even be detected in the fetus of mothers with hypercholesterolemia.117 Long-term suppression of COX-2-derived prostacyclin by coxibs would be expected to predispose to a gradual elevation in cardiovascular risk over time.76 In atherosclerosis studies in mice, disruption of the prostacyclin receptor IP gave rise to enhanced atherosclerotic lesions; in mice lacking the thromboxane receptor TP, the mice were protected in their development of atherosclerotic lesions.118,119 COX-2 inhibition studied in mouse models of atherosclerosis, on the other hand, has yielded variable effects in terms of lesion development.120-126 The reason for this variation could be attributable to the disparate actions of the different prostaglandins in atherothrombosis.76 Thus, blocking COX-2 downstream at the level of PGE2 synthesis by disruption of the main gene that makes PGE2 (called microsomal PGE synthase-1) can reduce atherothrombosis,108,127 but blocking COX-2-derived prostacyclin is detrimental.118,119 Therefore, during coxib administration the relative contributions of COX-2-derived PGE2 versus PGI2 in the lesion and vicinity of the lesions would be important in determining the outcome of COX-2 inhibition on atherosclerosis. In the setting of acute plaque rupture within a coronary artery, a profound loss of prostacyclin synthesis by a coxib would be expected to result in a severely reduced capacity to dissolve a developing thrombus.

In upsetting prostacyclin synthesis with a COX-2 inhibitor, an important restraint on endogenous mediators with an array of adverse cardiovascular effects is removed.

COX-2 is expressed within the kidney in the macula densa of the juxtaglomerular apparatus and other vascular regions of the kidney and is capable of generating prostacyclin.128-130 Prostacyclin within the kidney can regulate water and salt balance, glomerular filtration, and renal blood flow.130 Moreover, elegant studies in mice have shown that COX-2-derived prostacyclin is a potent renin secretagogue and regulator of renovascular hypertension.131 Loss of prostacyclin capability to signal through its receptor IP132,133 and inhibition of COX-2108 elevate blood pressure and augment the blood pressure response to dietary sodium. In addition, both disruption of the IP receptor and COX-2 inhibition modulate vascular remodeling induced by hemodynamic stress such as hypertension in vivo.76,96

One other important area should be mentioned relating to ischemic preconditioning. This phenomenon elicits marked COX-2 upregulation and activity in the heart that is protective in the latter phases against myocardial stunning and infarction.134 These beneficial actions appear to be mediated via either prostacyclin or PGE2 or perhaps both. This mechanism has been postulated to be integral to the process whereby the heart adapts to stress and an important cardioprotective function of COX-2.134

Back to Top | Article Outline

Chemical Properties of Coxibs

The coxibs, although generally belonging to the diaryl heterocycle class of drugs, each possess unique chemical, pharmacodynamic, and pharmacokinetic properties that influence their distribution in the body and locally within cell membranes within vascular tissue. Rofecoxib, possessing a methyl sulfone moiety, but not celecoxib/valdecoxib with a sulfonamide group, exhibited enhanced susceptibility to oxidative modification of low-density lipoproteins and lipids within membranes in vitro.135,136 This oxidative mechanism was independent of COX activity and could be detected by an elevation of isoprostanes, free radical-catalyzed oxidative stress markers. The prooxidant activity of rofecoxib could be inhibited by an antioxidant. A biophysical approach to this study using small-angle x-ray diffraction indicated that rofecoxib could disrupt the phospholipid headgroup to evoke a disordered conformation of the phospholipid acyl chains.135 This would result in altered packing of lipids within the membrane and a facilitation of lipid peroxidation by enhanced free radical diffusion. Celecoxib, on the other hand, bound the hydrocarbon core of the membrane, consistent with its greater lipophilicity, and did not disorder lipid structure. Thus, chemical properties of the coxibs could influence their relative cardiotoxicity. Whether these chemical property mechanisms are actually at play in vivo is subject to debate because measurement of urinary isoprostane levels at normal dosing with coxibs did not reveal elevation of these oxidative stress markers (FitzGerald GA, et al, unpublished observations).

A recent study found that rofecoxib but not celecoxib inhibited prostacyclin synthase activity.137 The inhibitory effect was not due to altered levels or changes in intracellular localization of the enzyme but was hypothesized to be a direct interaction of the drug with the enzyme by a noncompetitive mechanism perhaps involving the heme site.137

Back to Top | Article Outline

Enhanced Leukotriene Biosynthesis From COX-2 Inhibition Via Shunting of Arachidonic Acid

There have been suggestions 79,138 that COX-2 inhibition could shift arachidonic acid metabolism through the 5-lipoxygenase (5-LO)/leukotriene (LT) pathway by shunting of the common substrate. Recent findings implicate the 5-LO/LT pathway in cardiovascular disease, and this topic has been the subject of several recent reviews.139-141 Although the shunting hypothesis in relation to coxibs is intriguing, it has not yet been experimentally verified in any relevant animal or in vitro system to our knowledge. For this mechanism to work, one would have to envision that endothelial cell-released arachidonate would be taken up by inflammatory cells in intimate rolling/adherent contact with the endothelium to be converted to LTs. 5-LO is not usually expressed in endothelial cells, but it can be induced in some settings142; as a result, this particular mechanism remains speculative.

Back to Top | Article Outline

Modulation of Tissue Factor Expression

Tissue factor (TF), an important modulator of coagulation, influences the etiology of atherosclerosis and thrombosis.143 Prostacyclin can inhibit TF directly in monocytic cells and indirectly in endothelial cells.144 Celecoxib, but not rofecoxib or NS-398, reduced the induction of TF activity by the cytokine TNF-α in human aortic endothelial cells via a c-jun N-terminal kinase (JNK) pathway.145 This effect was observed with only 1 of 3 coxibs, so it was postulated to occur independently of its COX-2 activity via a direct effect on JNK phosphorylation. These results suggest, therefore, heterogeneity of response to coxibs. Rofecoxib would be predicted to have a more exaggerated response to plaque rupture (when TF is exposed) than for celecoxib.

Another mechanism for coxib -dependent prothrombotic actions has recently been proposed.146 Endothelial cell COX-2 metabolism of endocannabinoids coupled to prostacyclin synthase activates the nuclear receptor peroxisomal proliferator-activated receptor (PPAR)-delta that can led to a downregulation of TF expression and activity. Coxibs suppress PPAR-delta activity, which induces TF in vascular endothelium and leads to an elevation in circulating TF activity in vivo.

Back to Top | Article Outline

Differential Sensitivity of Coxibs to Endothelial and Platelet COX Inhibition

A recent article by Mitchell et al147 using cultured human aortic endothelial cells has offered another explanation for the mechanism of coxibs to promote increased thrombotic risk: preferential inhibition of endothelial COX-1-derived prostacyclin formation versus platelet COX-1-derived thromboxane formation. Thus, in static cultures (not exposed to laminar shear stress), only COX-1 was expressed, and COX-2 was present only if induced by an inflammatory stimulus (eg, interleukin-1β). Incubations of the aortic endothelial cells carried out in the presence of human platelet-rich plasma, to mimic drug binding to plasma proteins in vivo, revealed that COX-1 in endothelial cells was much more sensitive to inhibition by coxibs than COX-1 in platelets (2-log units for celecoxib and 1-log unit for rofecoxib). This differential inhibition of COX-1 in the 2 cell types was lost when the cells were homogenized, apparently because the cellular hydroperoxide environment was disrupted. Although coxibs generally are poor inhibitors of purified recombinant COX-1, COX-2 selectivity is lost at high enough concentrations. Moreover, in vitro assay conditions with arachidonate substrate and hydroperoxide strongly influence the ability of coxibs to inhibit COX-1.148 Therefore, these studies propose that drugs like rofecoxib and celecoxib can promote a prothrombotic environment. This is not a result of the fact that they inhibit COX-2 in endothelial cells, but because the postulate of a partisan sensitivity on endothelial prostacyclin formation by COX-1. One concern with this study is the concentration of coxib required to achieve the desired effects on COX-1 inhibition would likely not be attained in individuals taking these drugs. Also, it is unknown also whether the conditions of oxidant stress modeled in vitro pertain under any conditions in vivo.

Back to Top | Article Outline

CONCLUDING REMARKS

Taken together, the data support a detrimental effect of COX-2-derived prostacyclin inhibition that would be expected to lead to conditions predisposing to hypertension, increased susceptibility to thrombosis, and atherosclerosis. In upsetting prostacyclin synthesis with a COX-2 inhibitor, an important restraint on endogenous mediators with an array of adverse cardiovascular effects is removed. The consequences of this disruption are particularly heightened in people with compromised endothelial function (eg, atherosclerosis) or renal function (eg, salt retention, fluid imbalances), and administration of a COX-2 inhibitor would be expected to lower further the threshold for cardiovascular prothrombotic events in these individuals. Arteriolar vascular endothelium is an extremely rich source of prostacyclin synthase.52,53 The endothelial cells that line the intimal surface throughout the circulatory tree in an average-sized man are estimated to cover a surface area equivalent to a half dozen tennis courts.80 Taking into account (1) this huge surface area of the vascular endothelium and the great capacity of this tissue to produce prostacyclin, (2) the dynamic nature of endothelium and rapid regulation of COX-2, and (3) that COX-2 inhibitors reduce 65% to 80% of urinary prostacyclin metabolites, indices sensitive to local vascular stimulation and short-term systemic administration of prostacyclin,74,149 we are presented with compelling evidence that suppression of vascular prostacyclin synthesis by COX-2 inhibitors translates into the elevation of cardiovascular risk with these drugs.

Certain questions remain for future studies. Is there pharmacogenetic heterogeneity in the cardiovascular response of individuals to different members of the COX-2 inhibitor class? If so, can this be explained mechanistically? Can more direct approaches to assessment of the precise amounts of COX-1-derived versus COX-2-derived prostacyclin within the coronary vasculature be devised? Will individuals who are taking COX-2 -selective inhibitors long-term and who are at low cardiovascular risk undergo risk transformation, and can we understand at the biochemical, genetic, and pharmacological levels if or why this occurs and identify the patients at emerging risk? The answer to these and other questions will ultimately lead to the answer of another important question posed recently: is it possible to make a COX-2 inhibitor that's safe?150

Back to Top | Article Outline

REFERENCES

1. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001;294:1871-1875.
2. Needleman P, Turk J, Jakschik BA, et al. Arachidonic acid metabolism. Annu Rev Biochem. 1986;55:69-102.
3. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. 2004;56:387-437.
4. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem. 1996;271:33157-33160.
5. Bergstrom S, Samuelsson B. Isolation of prostaglandin E1 from human seminal plasma. Prostaglandins and related factors. 11. J Biol Chem. 1962;237:3005-3006.
6. Bergstrom S, Danielsson H, Samuelsson B. The enzymatic formation of prostaglandin e2 from arachidonic acid prostaglandins and related factors 32. Biochim Biophys Acta. 1964;90:207-210.
7. van Dorp D, Beerthuis RK, Nugteren DH, et al. The biosynthesis of prostaglandins. Biochim Biophys Acta. 1964;90:204-207.
8. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA. 1975;72:2994-2998.
9. Moncada S, Higgs J, Vane JR. Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet. 1977;1:18-20.
10. Moncada S, Gryglewski R, Bunting S, et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976;263:663-665.
11. Whittaker N, Bunting S, Salmon J, et al. The chemical structure of prostaglandin X (prostacyclin). Prostaglandins. 1976;12:915-928.
12. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231:232-235.
13. Flower R, Gryglewski R, Herbaczynska-Cedro K, et al. Effects of anti-inflammatory drugs on prostaglandin biosynthesis. Nat New Biol. 1972;238:104-106.
14. Ferreira SH, Moncada S, Vane JR. Prostaglandins and the mechanism of analgesia produced by aspirin-like drugs. Br J Pharmacol. 1973;49:86-97.
15. DeWitt DL, Smith WL. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA. 1988;85:1412-1416. Erratum in: Proc Natl Acad Sci USA. 1988;85:5056.
16. Merlie JP, Fagan D, Mudd J, et al. Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase). J Biol Chem. 1988;263:3550-3553.
17. Yokoyama C, Tanabe T. Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. Biochem Biophys Res Commun. 1989;165:888-894.
18. Rosen GD, Birkenmeier TM, Raz A, et al. Identification of a cyclooxygenase-related gene and its potential role in prostaglandin formation. Biochem Biophys Res Commun. 1989;164:1358-1365.
19. Raz A, Wyche A, Needleman P. Temporal and pharmacological division of fibroblast cyclooxygenase expression into transcriptional and translational phases. Proc Natl Acad Sci USA. 1989;86:1657-1661.
20. Fu JY, Masferrer JL, Seibert K, et al. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem. 1990;265:16737-16740.
21. Han JW, Sadowski H, Young DA, et al. Persistent induction of cyclooxygenase in p60v-src-transformed 3T3 fibroblasts. Proc Natl Acad Sci USA. 1990;87:3373-3377.
22. Xie WL, Chipman JG, Robertson DL, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA. 1991;88:2692-2696.
23. Kujubu DA, Fletcher BS, Varnum BC, et al. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem. 1991;266:12866-12872.
24. Fletcher BS, Kujubu DA, Perrin DM, et al. Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. J Biol Chem. 1992;267:4338-4344.
25. Kujubu DA, Reddy ST, Fletcher BS, et al. Expression of the protein product of the prostaglandin synthase-2/TIS10 gene in mitogen-stimulated Swiss 3T3 cells. J Biol Chem. 1993;268:5425-5430.
26. Funk CD, Funk LB, Kennedy ME, et al. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J. 1991;5:2304-2312.
27. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA. 1992;89:7384-7388.
28. Jones DA, Carlton DP, McIntyre TM, et al. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem. 1993;268:9049-9054.
29. Crofford LJ, Wilder RL, Ristimaki AP, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. J Clin Invest. 1994;93:1095-1101.
30. Seibert K, Zhang Y, Leahy K, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA. 1994;91:12013-12017.
31. Masferrer JL, Zweifel BS, Manning PT, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA. 1994;91:3228-3232.
32. Copeland RA, Williams JM, Giannaras J, et al. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad Sci USA. 1994;91:11202-11206.
33. Laneuville O, Breuer DK, Dewitt DL, et al. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 1994;271:927-934.
34. Patrignani P, Panara MR, Greco A, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther. 1994;271:1705-1712.
35. Brideau C, Kargman S, Liu S, et al. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res. 1996;45:68-74.
36. Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA. 1999;96:7563-7568. Erratum in: Proc Natl Acad Sci USA. 1999;96:9666.
37. Penning TD, Talley JJ, Bertenshaw SR, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem. 1997;40:1347-1365.
38. Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum. 1998;41:1591-1602.
39. Chan CC, Boyce S, Brideau C, et al. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther. 1999;290:551-560.
40. Ehrich EW, Dallob A, De Lepeleire I, et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther. 1999;65:336-347.
41. Gierse JK, Koboldt CM, Walker MC, et al. Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem J. 1999;339:607-614.
42. Riendeau D, Percival MD, Brideau C, et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther. 2001;296:558-566.
43. Tacconelli S, Capone ML, Sciulli MG, et al. The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. Curr Med Res Opin. 2002;18:503-511.
44. Gierse JK, Zhang Y, Hood WF, et al. Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity. J Pharmacol Exp Ther. 2005;312:1206-1212.
45. Bombardier C, Laine L, Reicin A, et al; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520-1528.
46. Burke A, Smyth E, FitzGerald GA. Analgesic-antipyretic agents; pharmacotherapy of gout. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th Edition. New York: McGraw-Hill; 2006:671-715.
47. FitzGerald GA. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov. 2003;2:879-890.
48. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433-442.
49. Talley JJ, Brown DL, Carter JS, et al. 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem. 2000;43:775-777.
50. Moncada S. Eighth Gaddum Memorial Lecture. University of London Institute of Education, December 1980. Biological importance of prostacyclin. Br J Pharmacol. 1982;76:3-31.
51. Baenziger NL, Becherer PR, Majerus PW. Characterization of prostacyclin synthesis in cultured human arterial smooth muscle cells, venous endothelial cells and skin fibroblasts. Cell. 1979;16:967-974.
52. Moncada S, Herman AG, Higgs EA, et al. Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res. 1977;11:323-344.
53. Miyata A, Hara S, Yokoyama C, et al. Molecular cloning and expression of human prostacyclin synthase. Biochem Biophys Res Commun. 1994;200:1728-1734.
54. Gryglewski RJ, Korbut R, Ocetkiewicz A. Generation of prostacyclin by lungs in vivo and its release into the arterial circulation. Nature. 1978;273:765-767.
55. Smyth E, Burke A, FitzGerald GA. Lipid-derived autocoids: eicosanoids and platelet-activating factor. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th Edition. New York: McGraw-Hill; 2006:653-670.
56. Kothapalli D, Stewart SA, Smyth EM, et al. Prostacyclin receptor activation inhibits proliferation of aortic smooth muscle cells by regulating cAMP response element-binding protein- and pocket protein-dependent cyclin a gene expression. Mol Pharmacol. 2003;64:249-258.
57. Smyth E, Funk CD. Platelet eicosanoids. In: Hemostasis and Thrombosis, 5th Edition. Colman, Marder, Clowes, George, Goldhaber, editors; London: Lippincott Williams & Wilkens; 2006:583-590.
58. Needleman P, Moncada S, Bunting S, et al. Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature. 1976;261:558-560.
59. Halushka PV, Mais DE, Saussy DL Jr. Platelet and vascular smooth muscle thromboxane A2/prostaglandin H2 receptors. Fed Proc. 1987;46:149-153.
60. Dorn GW 2nd. Role of thromboxane A2 in mitogenesis of vascular smooth muscle cells. Agents Actions Suppl. 1997;48:42-62.
61. Smith JB. The prostanoids in hemostasis and thrombosis: a review. Am J Pathol. 1980;99:743-804.
62. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J. 2002;324:71-86. Erratum: Br Med J. 2002;324:141.
63. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135.
64. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed). 1988;296:313-316.
65. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet. 1998;351:233-241.
66. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet. 2001;357:89-95. Erratum: Lancet. 2001;357:1134.
67. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-1304.
68. Hennekens CH. Aspirin in chronic cardiovascular disease and acute myocardial infarction. Clin Cardiol. 1990;Suppl 5:V62-V66; discussion V67-72.
69. Bunting S, Moncada S, Vane JR. The prostacyclin-thromboxane A2 balance: pathophysiological and therapeutic implications. Br Med Bull. 1983;39:271-276.
70. FitzGerald GA, Catella F, Oates JA. Eicosanoid biosynthesis in human cardiovascular disease. Hum Pathol. 1987;18:248-252.
71. Catella F, Healy D, Lawson JA, et al. 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci USA. 1986;83:5861-5865.
72. Catella F, Nowak J, FitzGerald GA. Measurement of renal and non-renal eicosanoid synthesis. Am J Med. 1986;81:23-29.
73. Patrono C, Ciabattoni G, Pugliese F, et al. Estimated rate of thromboxane secretion into the circulation of normal humans. J Clin Invest. 1986;77:590-594.
74. FitzGerald GA, Brash AR, Falardeau P, et al. Estimated rate of prostacyclin secretion into the circulation of normal man. J Clin Invest. 1981;68:1272-1276.
75. Brash AR, Jackson EK, Saggese CA, et al. Metabolic disposition of prostacyclin in humans. J Pharmacol Exp Ther. 1983;226:78-87.
76. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116:4-15.
77. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002;296:539-541.
78. Flavahan NA. Balancing prostanoid activity in the human vascular system. Trends Pharmacol Sci. 2007;28:106-110.
79. Antman EM, DeMets D, Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation. 2005;112:759-770.
80. Schafer AI. Vascular endothelium: in defense of blood fluidity. J Clin Invest. 1997;99:1143-1144.
81. FitzGerald GA, Oates JA, Hawiger J, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983;71:676-688.
82. Knapp HR, Healy C, Lawson J, et al. Effects of low-dose aspirin on endogenous eicosanoid formation in normal and atherosclerotic men. Thromb Res. 1988;50:377-386.
83. Clarke RJ, Mayo G, Price P, et al. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med. 1991;325:1137-1141.
84. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA. 1999;96:272-277. Erratum: Proc Natl Acad Sci USA. 1999;96:5890.
85. Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther. 1999;289:735-741.
86. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809-1817.
87. Belton O, Byrne D, Kearney D, et al. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation. 2000;102:840-845.
88. Topper JN, Cai J, Falb D, et al. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA. 1996;93:10417-10422.
89. Inoue H, Taba Y, Miwa Y, et al. Transcriptional and posttranscriptional regulation of cyclooxygenase-2 expression by fluid shear stress in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2002;22:1415-1420.
90. Patrignani P, Di Francesco L, Piccoli A, et al. Differential contribution of cycloooxygenase-isozymes to the generation of prostacyclin and prostaglandin E2 by endothelial cells in response to steady laminar shear stress. Arterioscler Thromb Vasc Biol. 2007;27:e75 (Absract p217).
91. Davies PF, Remuzzi A, Gordon EJ, et al. Turbulent fluid shear stress induces vascular endothelial cell turnover in vitro. Proc Natl Acad Sci USA. 1986;83:2114-2117.
92. Schonbeck U, Sukhova GK, Graber P, et al. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol. 1999;155:1281-1291.
93. Baker CS, Hall RJ, Evans TJ, et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol. 1999;19:646-655.
94. Stemme V, Swedenborg J, Claesson H, et al. Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries. Eur J Vasc Endovasc Surg. 2000;20:146-152.
95. Kawka DW, Ouellet M, Hetu PO, et al. Double-label expression studies of prostacyclin synthase, thromboxane synthase and COX isoforms in normal aortic endothelium. Biochim Biophys Acta. 2007;1771:45-54.
96. Rudic RD, Brinster D, Cheng Y, et al. COX-2-derived prostacyclin modulates vascular remodeling. Circ Res. 2005;96:1240-1247.
97. Bishop-Bailey D, Pepper JR, Haddad EB, et al. Induction of cyclooxygenase-2 in human saphenous vein and internal mammary artery. Arterioscler Thromb Vasc Biol. 1997;17:1644-1648.
98. Loftin CD, Trivedi DB, Tiano HF, et al. Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2. Proc Natl Acad Sci USA. 2001;98:1059-1064.
99. Yokoyama U, Minamisawa S, Quan H, et al. Chronic activation of the prostaglandin receptor EP4 promotes hyaluronan-mediated neointimal formation in the ductus arteriosus. J Clin Invest. 2006;116:3026-3034.
100. Jongstra-Bilen J, Haidari M, Zhu SN, et al. Low-grade chronic inflammation in regions of the normal mouse arterial intima predisposed to atherosclerosis. J Exp Med. 2006;203:2073-2083.
101. Ristimaki A, Garfinkel S, Wessendorf J, et al. Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation. J Biol Chem. 1994;269:11769-11775.
102. Dixon DA, Kaplan CD, McIntyre TM, et al. Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3′-untranslated region. J Biol Chem. 2000;275:11750-11757.
103. Capone ML, Tacconelli S, Di Francesco L, et al. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat. 2007;82:85-94.
104. Mbonye UR, Wada M, Rieke CJ, et al. The 19-amino acid cassette of cyclooxygenase-2 mediates entry of the protein into the endoplasmic reticulum-associated degradation system. J Biol Chem. 2006;281:35770-35778.
105. Yu Y, Fan J, Hui Y, et al. Targeted cyclooxygenase gene (ptgs) exchange reveals discriminant isoform functionality. J Biol Chem. 2007;282:1498-1506.
106. Davies PF, Barbee KA, Volin MV, et al. Spatial relationships in early signaling events of flow-mediated endothelial mechanotransduction. Annu Rev Physiol. 1997;59:527-549.
107. Passerini AG, Polacek DC, Shi C, et al. Coexisting proinflammatory and antioxidative endothelial transcription profiles in a disturbed flow region of the adult porcine aorta. Proc Natl Acad Sci USA. 2004;101:2482-2487.
108. Cheng Y, Wang M, Yu Y, et al. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest. 2006;116:1391-1399.
109. Yu Y, Fan J, Chen XS, et al. Genetic model of selective COX2 inhibition reveals novel heterodimer signaling. Nat Med. 2006;12:699-704.
110. Hennan JK, Huang J, Barrett TD, et al. Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation. 2001;104:820-825.
111. Zewde T, Mattson DL. Inhibition of cyclooxygenase-2 in the rat renal medulla leads to sodium-sensitive hypertension. Hypertension. 2004;44:424-428.
112. Qi Z, Hao CM, Langenbach RI, et al. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest. 2002;110:61-69. Erratum: J Clin Invest. 2002;110:419.
113. Pidgeon GP, Tamosiuniene R, Chen G, et al. Intravascular thrombosis after hypoxia-induced pulmonary hypertension: regulation by cyclooxygenase-2. Circulation. 2004;110:2701-2707.
114. Buerkle MA, Lehrer S, Sohn HY, et al. Selective inhibition of cyclooxygenase-2 enhances platelet adhesion in hamster arterioles in vivo. Circulation. 2004;110:2053-2059.
115. Murata T, Ushikubi F, Matsuoka T, et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature. 1997;388:678-682.
116. Rabausch K, Bretschneider E, Sarbia M, et al. Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins. Circ Res. 2005;96:e1-e6.
117. Napoli C, D'Armiento FP, Mancini FP, et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest. 1997;100:2680-2690.
118. Kobayashi T, Tahara Y, Matsumoto M, et al. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest. 2004;114:784-794.
119. Egan KM, Lawson JA, Fries S, et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science. 2004;306:1954-1957.
120. Burleigh ME, Babaev VR, Oates JA, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation. 2002;105:1816-1823.
121. Olesen M, Kwong E, Meztli A, et al. No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice. Scand Cardiovasc J. 2002;36:362-367.
122. Rott D, Zhu J, Burnett MS, et al. Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice. J Am Coll Cardiol. 2003;41:1812-1819.
123. Burleigh ME, Babaev VR, Yancey PG, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. J Mol Cell Cardiol. 2005;39:443-452.
124. Egan KM, Wang M, Fries S, et al. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation. 2005;111:334-342.
125. Metzner J, Popp L, Marian C, et al. The effects of COX-2 selective and non-selective NSAIDs on the initiation and progression of atherosclerosis in ApoE(−/−) mice. J Mol Med. 2007;85:623-633
126. Bea F, Blessing E, Bennett BJ, et al. Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis. Cardiovasc Res. 2003;60:198-204.
127. Wang M, Zukas AM, Hui Y, et al. Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc Natl Acad Sci USA. 2006;103:14507-14512.
128. Harris RC, McKanna JA, Akai Y, et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest. 1994;94:2504-2510.
129. Therland KL, Stubbe J, Thiesson HC, et al. Cycloxygenase-2 is expressed in vasculature of normal and ischemic adult human kidney and is colocalized with vascular prostaglandin E2 EP4 receptors. J Am Soc Nephrol. 2004;15:1189-1198.
130. Harris RC. Cyclooxygenase-2 and the kidney: functional and pathophysiological implications. J Hypertens Suppl. 2002;20:S3-S9.
131. Fujino T, Nakagawa N, Yuhki K, et al. Decreased susceptibility to renovascular hypertension in mice lacking the prostaglandin I2 receptor IP. J Clin Invest. 2004;114:805-812.
132. Watanabe H, Katoh T, Eiro M, et al. Effects of salt loading on blood pressure in mice lacking the prostanoid receptor gene. Circ J. 2005;69:124-126.
133. Francois H, Athirakul K, Howell D, et al. Prostacyclin protects against elevated blood pressure and cardiac fibrosis. Cell Metab. 2005;2:201-207.
134. Bolli R, Shinmura K, Tang XL, et al. Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res. 2002;55:506-519.
135. Mason RP, Walter MF, McNulty HP, et al. Rofecoxib increases susceptibility of human LDL and membrane lipids to oxidative damage: a mechanism of cardiotoxicity. J Cardiovasc Pharmacol. 2006;47(Suppl 1):S7-S14.
136. Walter MF, Jacob RF, Day CA, et al. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis. 2004;177:235-243.
137. Griffoni C, Spisni E, Strillacci A, et al. Selective inhibition of prostacyclin synthase activity by rofecoxib. J Cell Mol Med. 2007;11:327-338.
138. Zarraga IG, Schwarz ER. Coxibs and heart disease: what we have learned and what else we need to know. J Am Coll Cardiol. 2007;49:1-14.
139. Lotzer K, Funk CD, Habenicht AJ. The 5-lipoxygenase pathway in arterial wall biology and atherosclerosis. Biochim Biophys Acta. 2005;1736:30-37.
140. Funk CD. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev Drug Discov. 2005;4:664-672.
141. Mehrabian M, Allayee H. 5-lipoxygenase and atherosclerosis. Curr Opin Lipidol. 2003;14:447-457.
142. Wright L, Tuder RM, Wang J, et al. 5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. Am J Respir Crit Care Med. 1998;157:219-229.
143. Eilertsen KE, Osterud B. Tissue factor: (patho)physiology and cellular biology. Blood Coagul Fibrinolysis. 2004;15:521-538.
144. Crutchley DJ, Conanan LB, Toledo AW, et al. Effects of prostacyclin analogues on human endothelial cell tissue factor expression. Arterioscler Thromb. 1993;13:1082-1089.
145. Steffel J, Hermann M, Greutert H, et al. Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation. Circulation. 2005;111:1685-1689.
146. Ghosh M, Wang H, Ai Y, et al. COX-2 suppesses tissue factor expression via endocannabinoid-directed PPARδ activation. J Exp Med. 2007;204:253-261.
147. Mitchell JA, Lucas R, Vojnovic I, et al. Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. FASEB J. 2006;20:2468-2475.
148. Riendeau D, Charleson S, Cromlish W, et al. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Can J Physiol Pharmacol. 1997;75:1088-1095.
149. Roy L, Knapp HR, Robertson RM, et al. Endogenous biosynthesis of prostacyclin during cardiac catheterization and angiography in man. Circulation. 1985;71:434-440.
150. Nissen S, Arnett D, Woodcock J, et al. Is it possible to make a COX-2 inhibitor that's safe? Nat Med. 2007;13:653.
Keywords:

prostacyclin; coxib; thromboxane; platelet; vascular

© 2007 Lippincott Williams & Wilkins, Inc.